IDH1 and acute myeloid leukemia: Ivosidenib trials were successful for the treatment of IDH1-mutated relapsed or refractory AML, with an ORR of 41.6%, and later on also for the treatment of newly diagnosed IDH1-mutant AML, with ORR of 54.5% [145,146].